RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:213772

Adenocarcinoma of the cervix uteri

high confidenceDisorder

Also known as: Cervical adenocarcinoma

Publications

11,518

95.9th percentile

Trials

59

Interventional, condition-specific

Researchers

1,141

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (11)

adenocarcinoma - cervix · adenocarcinoma of cervix · adenocarcinoma of cervix uteri · adenocarcinoma of the cervix · adenocarcinoma of the cervix uteri · adenocarcinoma of the uterine cervix · adenocarcinoma of uterine cervix · cervical adenocarcinoma · cervix adenocarcinoma · cervix uteri adenocarcinoma · uterine cervix adenocarcinoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    11,518 matched papers (6,590 in last 10 years) Source

  3. Phenotype characterisedNot found

    No HPO disease–phenotype associations via Monarch for these Mondo IDs

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    59 matched on ClinicalTrials.gov (10 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

11

Drugs / clinical candidates · MONDO_0005153

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

11,518

11,518 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

11,518 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

6,590 in the last 10 years · high confidence · 95.9th percentile (publications denominator)

Phrase hits: 11,518 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,141

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Liu Y8 papers · 2026

    Department of Obstetrics and Gynecology, The 964th Hospital, Changchun, Jilin, China.

    Papers in Europe PMC
  2. 02
    Zhang H8 papers · 2026

    Department of Radiotherapy, The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China.

    Papers in Europe PMC
  3. 03
    Zhang Y8 papers · 2026

    Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.

    Papers in Europe PMC
  4. 04
    Wang Y7 papers · 2026

    Pathology Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

    Papers in Europe PMC
  5. 05
    Wang J6 papers · 2026

    Department of Pathology, The Affiliated Hospital of Qingdao University, No. 1677 Wutaishan Road, Qingdao, 266555, Shandong, China. wangjigang@qdu.edu.cn.

    Papers in Europe PMC
  6. 06
    Zhang L6 papers · 2026

    Department of Obstetrics, Gynecology and Reproductive Sciences, Air Force Medical University, Air Force Medical Center, PLA, Beijing, China.

    Papers in Europe PMC
  7. 07
    Chen L5 papers · 2026

    Department of Gynecology, Fujian Maternity and Child Health Hospital, College of Clinical Medical for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China.

    Papers in Europe PMC
  8. 08
    Li L5 papers · 2026

    NHC Key Laboratory of Cancer Metabolism, Department of Gynecology, Fujian Cancer Hospital, Clinical Oncology School of Fujian Medical University, Fuzhou, China.

    Papers in Europe PMC
  9. 09
    Li Y5 papers · 2026

    Department of Gynecology, The First People's Hospital of Jiande, Jiande, China.

    Papers in Europe PMC
  10. 10
    Wang L5 papers · 2026

    Department of Obstetrics and Gynecology, The 964th Hospital, Changchun, Jilin, China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

59

interventional trials for this specific condition

59 interventional trials matched this specific condition name; 10 currently recruiting in our sample. 3,633 trials are registered for adenocarcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026

59 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 97.5th percentile).

high confidence · 97.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

59 interventional trials matched after quoted-phrase search and title/condition post-filter.

Broader category: adenocarcinoma

3,633

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Observational and natural-history studies

9 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 42 · after dedupe 42 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 42 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (42)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Adenocarcinoma of the cervix uteri — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Adenocarcinoma of the cervix uteri" OR "Adenocarcinoma of cervix uteri" OR "Cervical adenocarcinoma" OR "adenocarcinoma - cervix" OR "adenocarcinoma of cervix" OR "adenocarcinoma of the cervix" OR "adenocarcinoma of the uterine cervix" OR "adenocarcinoma of uterine cervix" OR "cervix adenocarcinoma" OR "cervix uteri adenocarcinoma" OR "uterine cervix adenocarcinoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Adenocarcinoma of the cervix uteri" OR "Adenocarcinoma of cervix uteri" OR "Cervical adenocarcinoma" OR "adenocarcinoma - cervix" OR "adenocarcinoma of cervix" OR "adenocarcinoma of the cervix" OR "adenocarcinoma of the uterine cervix" OR "adenocarcinoma of uterine cervix" OR "cervix adenocarcinoma" OR "cervix uteri adenocarcinoma" OR "uterine cervix adenocarcinoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 59 interventional · 9 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"adenocarcinoma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T09:38:17.738Z